Outlook Therapeutics Resubmits FDA Application
Outlook Therapeutics, Inc. resubmitted the Biologics License Application for ONS-5010 to the U.S. Food and Drug Administration on June 1, 2026. The company issued a press release announcing the resubmission.
Topics
Developing
- 882d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 882d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 882d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 882d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
Bluesky Social
“On June 1, 2026, Outlook Therapeutics, Inc issued a press release announcing that it has resubmitted the Biologics License Application for ONS-5010 to the U.S. Food and Drug Administration.”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade